Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HSV-2 Infection Clear all
Terminated Phase 4 Interventional Results available

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Jul 22, 2026, 5:01 PM EDT
Withdrawn Not applicable Interventional

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721
View directory record Official record
Conditions
Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions
Placebo, Valacyclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru

NCT00023582
View directory record Official record
Conditions
HIV Infections, Herpes Genitalis, HIV Seronegativity, Syphilis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

NCT02432404
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
NuvaRing
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Herpes Simplex Type 1 Suppression in Hepatitis C

NCT01580995
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational

HSV-2 Shedding Resolution After Acyclovir Treatment

NCT00495573
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 29, 2010 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes

NCT02986802
View directory record Official record
Conditions
HSV-2 Infection, PreTerm Birth, Pregnancy Complications
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
89,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
View directory record Official record
Conditions
Genital Herpes, HIV Infection
Interventions
valacyclovir, acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 2 Interventional

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

NCT02300142
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg)
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Jul 22, 2026, 5:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

NCT01453075
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Jul 22, 2026, 5:01 PM EDT
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 22, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT01658826
View directory record Official record
Conditions
Genital Herpes
Interventions
AIC316, Valacyclovir
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Indianapolis, Indiana • Portland, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jul 22, 2026, 5:01 PM EDT